{
    "clinical_study": {
        "@rank": "72375", 
        "arm_group": [
            {
                "arm_group_label": "1. ASP1707 lowest dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2 ASP1707 higher dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "3. ASP1707 Highest dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Three groups of 8 Japanese males are given single ascending doses of ASP1707 or placebo to\n      assess the safety and tolerability, and to evaluate how it is absorbed, metabolized and\n      distributed through the body."
        }, 
        "brief_title": "A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects", 
        "completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Subjects", 
        "detailed_description": {
            "textblock": "The first group receives the lowest dose while the last group receives the highest dose.\n      ASP1707 or matching placebo is administered as a single dose under fasted conditions.\n\n      Screening takes place from Day -22 to Day -2. Subjects are admitted to the clinic on Day -1\n      and remain until Day 5. An end of study visit (ESV) takes place 7-14 days after discharge.\n\n      Escalation to the next higher dose takes place after review of the safety and tolerability\n      data from the previous dose.\n\n      Safety assessments are performed throughout the study. Plasma and urine samples are\n      collected for pharmacokinetics (PK) analysis. Serum samples are collected for\n      pharmacodynamic (PD) analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Born in Japan\n\n          -  Both parents are of Japanese descent\n\n          -  Time residing outside Japan does not exceed 5 years\n\n          -  Maintains Japanese life style including diet\n\n          -  Male subject must be non-fertile, i.e. surgically sterilized or must practice an\n             effective contraceptive method\n\n        Exclusion Criteria:\n\n          -  Subjects with out-of-range T levels in serum at screening\n\n          -  Subjects with any history of cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146742", 
            "org_study_id": "1707-CL-0002", 
            "secondary_id": "2010-024040-15"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1. ASP1707 lowest dose", 
                    "2 ASP1707 higher dose", 
                    "3. ASP1707 Highest dose"
                ], 
                "description": "oral", 
                "intervention_name": "ASP1707", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1. ASP1707 lowest dose", 
                    "2 ASP1707 higher dose", 
                    "3. ASP1707 Highest dose"
                ], 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ASP1707", 
            "Japanese subjects", 
            "Safety", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Harrow", 
                    "country": "United Kingdom", 
                    "zip": "HA1 3UJ"
                }, 
                "name": "Parexel Early Phase"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double Blind, Randomized and Placebo Controlled Ascending Single Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ASP1707 in Healthy Young Japanese Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Clinical Study Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability measured by Adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Day -2 to ESV (up to Day 19)"
            }, 
            {
                "measure": "Safety and tolerability measured by physical examination (PE)", 
                "safety_issue": "Yes", 
                "time_frame": "Day -2 to ESV (up to Day 19)"
            }, 
            {
                "measure": "Safety and tolerability measured by vital signs (VS)", 
                "safety_issue": "Yes", 
                "time_frame": "Day -2 to ESV (up to Day 19)"
            }, 
            {
                "measure": "Safety and tolerability measured by laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Day -2 to ESV (up to Day 19)"
            }, 
            {
                "measure": "Safety and tolerability measured by 12 lead electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "Day -2 to ESV (up to Day 19)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146742"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf), AUC from time of dosing until last measurable concentration (AUClast), time to reach quantifiable concentrations (tlag), maximum concentration (Cmax), time to attain Cmax (tmax), terminal elimination half-life (t1/2), apparent volume of distribution (Vz/F), apparent clearance (CL/F)", 
                "measure": "PK profile of single ascending doses of ASP1707 in plasma", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 5"
            }, 
            {
                "description": "amount excreted unchanged into urine (Ae) from time of dosing until last measurable concentration (Aelast), Ae extrapolated to time = infinity (Aeinf), Ae from time of dosing until last measurable concentration as percentage of total dose (Aelast%), Ae extrapolated to time = infinity as percentage of total dose (Aeinf%), renal clearance (CLR)", 
                "measure": "PK profile of single ascending doses of ASP1707 in urine", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 5"
            }, 
            {
                "description": "measured by minimum concentration (Cmin), time to attain Cmin (tmin), maximal %Reduction T only: number and percentage of subjects with T castration level (= T < 500 pg/mL) after single dose, time of onset and offset of T < 500 pg/mL after single dose, duration of T <500 pg/mL after single dose", 
                "measure": "Pharmacodynamics of Testosterone (T)", 
                "safety_issue": "No", 
                "time_frame": "Day -1 to ESV"
            }, 
            {
                "description": "measured by minimum concentration (Cmin), time to attain Cmin (tmin), maximal %Reduction T only: number and percentage of subjects with T castration level (= T < 500 pg/mL) after single dose, time of onset and offset of T < 500 pg/mL after single dose, duration of T <500 pg/mL after single dose", 
                "measure": "Pharmacodynamics of Luteinizing Hormone (LH)", 
                "safety_issue": "No", 
                "time_frame": "Day -1 to ESV"
            }, 
            {
                "description": "measured by minimum concentration (Cmin), time to attain Cmin (tmin), maximal %Reduction T only: number and percentage of subjects with T castration level (= T < 500 pg/mL) after single dose, time of onset and offset of T < 500 pg/mL after single dose, duration of T <500 pg/mL after single dose", 
                "measure": "Pharmacodynamics of Follicle-Stimulating Hormone (FSH) levels", 
                "safety_issue": "No", 
                "time_frame": "Day -1 to ESV"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}